Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.59 |
| ▸ | MYC | P01106 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056180 | 0.87 | PKM (0.62) | PKMDDAH1POLBALPLMAPK1 | |
| SCHEMBL31298007 | 0.81 | PKM (0.96) | PKMDDAH1POLBKDM4EGAA | |
| SCHEMBL336412 | 0.81 | PKM (0.96) | PKMDDAH1POLBKDM4EGAA | |
| SCHEMBL711507 | 0.80 | PKM (0.71) | PKMDDAH1POLBGAASMN1; SMN2 | |
| SCHEMBL31734838 | 0.80 | PKM (0.71) | PKMDDAH1POLBGAASMN1; SMN2 | |
| SCHEMBL19001265 | 0.80 | PKM (0.42) | PKMDDAH1MYCALPLMAPK1 | |
| Hydrochloric Acid SCHEMBL30689215 | 0.79 | PKM (1.00) | PKMDDAH1POLBKDM4EGAA | |
| Hydrochloric Acid SCHEMBL5205174 | 0.79 | PKM (1.00) | PKMDDAH1POLBKDM4EGAA | |
| Hydrochloric Acid SCHEMBL5973175 | 0.79 | PKM (1.00) | PKMDDAH1POLBKDM4EGAA | |
| SCHEMBL21941037 | 0.79 | PKM (0.69) | PKMDDAH1POLBGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| WO-2017181177-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS | Epizyme, Inc. (US) | 2017-10-19 | — | — | WO | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160083397-A1 | PARTHENOLIDE DERIVATIVES AND THEIR MODULATION OF PROCESSES CONTROLLED BY REGULATED TRANSLATION | BIOVENTURES, LLC | 2016-03-24 | — | — | US | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | SCHREIBER STUART L | 2008-03-20 | — | — | US | disclosed |
| US-7186709-B2 | Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070916-A1 | Dihydropyrancarboxamides and uses thereof | CCNA1, DPYD, DHFR | PKM 1032/4885DDAH1 137/4885MYC 1274/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | PKM 150/4885DDAH1 1450/4885MYC 32/4885 |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | GAP43, DGAT2, DCX | PKM 4289/4885DDAH1 257/4885MYC 1984/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | PKM 1565/4885DDAH1 882/4885MYC 4468/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | PKM 1645/4885DDAH1 3785/4885MYC 1387/4885 |
| US-20160083397-A1 | PARTHENOLIDE DERIVATIVES AND THEIR MODULATION OF PROCESSES CONTROLLED BY REGULATED TRANSLATION | EIF4EBP1, RIOX2, RPL7A | PKM 1546/4885DDAH1 2159/4885MYC 75/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | PKM 1941/4885DDAH1 1113/4885MYC 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.